PRIA Logo™
119-hr-3546119th Congress

Prescription Drug Price Relief Act of 2025

Sponsored By: Representative Khanna, Ro [D-CA-17]

Introduced

Summary

Breaking monopolies to lower brand-name drug prices. The bill would set a government-wide framework to identify brand-name drugs priced far above international benchmarks and to remove exclusivities so open, non-exclusive licenses and waivers speed generic and biosimilar entry.

Show full summary
  • Patients and families: Would aim to make drugs more affordable by fast-tracking generics and biosimilars when a drug is flagged as excessively priced.
  • Brand manufacturers: Would face removal of government-granted monopolies in some cases and would be required to offer non-exclusive licenses with reasonable royalty payments. The bill would also mandate price reporting and allow penalties for noncompliance.
  • Transparency and competition: Would create a public pricing database and annual congressional reports, prohibit anticompetitive behavior around licensing, and set definitions and processes across eight sections to guide enforcement.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & CoSponsors

Sponsor

Khanna, Ro [D-CA-17]

CA • D

Cosponsors

  • Rep. Schakowsky, Janice D. [D-IL-9]

    IL • D

    Sponsored 5/21/2025

  • Rep. Jayapal, Pramila [D-WA-7]

    WA • D

    Sponsored 5/23/2025

  • Rep. Omar, Ilhan [D-MN-5]

    MN • D

    Sponsored 6/3/2025

  • Rep. Ansari, Yassamin [D-AZ-3]

    AZ • D

    Sponsored 7/22/2025

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation